EUCTR2015-003761-28-DE进行中（未招募）1 期
GLYCEMIC CONTROL AND TREATMENT SATISFACTION USING FINESSE VERSUS PEN FOR INITIATING BOLUS INSULIN DOSING IN TYPE 2 DIABETES MELLITUS PATIENTS NOT ACHIEVING GLYCEMIC TARGETS ON BASAL INSULIN WITH/WITHOUT ANTI-HYPERGLYCEMIC AGENTS
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 312
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •a) Patient is willing to provide written informed consent prior to enrollment and agrees to follow the protocol.
- •b) Age 22 – 75 years.
- •c) Known clinical diagnosis of type 2 diabetes according to ADA/EASD 31, 32 criteria. d) Treated with basal insulin for = 6 months (e.g., Lantus® [Glargine], Levemir®
- •[Detemir], Tresiba® [Degludec], and NPH [Neutral Protamine Hagedorn]), with current dose stable for = 6 weeks at = 0.3 U/kg/day not to exceed 100U/day, with/without any combination of AHA, and in whom the HCP feels advancement from basal to basal and bolus therapy is needed for the patient. Note: if basal
- •insulin dose is < 0.3 U/kg/day at visit 1, and, if clinically indicated (e.g., based on A1C, FPG), the Investigator and/or patient’s HCP is encouraged to adjust basal insulin to doses = 0.3 U/kg and re-screen in = 2months after the first screen.
- •e) A1C 7.5-11.0% at screening visit 1. Note: To account for A1C assay variability, per investigator discretion, patients are allowed one re-testing of A1C (to be performed in a freshly drawn sample) within 7 days of the first testing if, their basal insulin dose is =0.3 U/kg and if the A1C level was as low as 7.2% or as high as 11.3% and and the retested value will be used for determining eligibility.
- •Patients will also be allowed one A1C re-screening, if their basal insulin dose is =
- •0.3 U/kg and if their A1C level at the first screen was as low as 7.2% or as high
- •as 11.3%. The re-screen should be performed in = 2 months after the first screen.
- •f)Patients who already perform SMBG and who are willing to test BG over the course of the study a minimum of 4 times per day as well as 7 times per day for 3
- •days during baseline and in the week prior to follow-up visit 6C (week 24) and visit 8 (week 44) (for a total of 9 days).
- •g) In the subset of sites that are participating in CGM: Patients who are willing to wear a CGM for one to two weeks during the baseline period and for one to two
- •weeks prior to follow-up visit 6C at week 24. Exclude patients who are unable or unwilling to not use acetaminophen/paracetamol for at least 4 hours prior to CGM and during CGM.
- •h)Negative urine ß-HCG pregnancy test at screening and randomization for women
- •of childbearing age. Women who are capable of pregnancy and who are heterosexually active, must be practicing an effective method of birth control including hormonal prescription oral contraceptives, contraceptive injections, contraceptive patch, intrauterine device, double barrier method (e.g., condoms, diaphragm, or cervical cap, with spermicidal foam, cream or gel) or male partner sterilization, and consistent with local regulations regarding use of birth control methods for patients participating in clinical studies, for the duration of their participation in the study. (Note: women who are not heterosexually active at screening must agree to utilize effective method of birth control if they become heterosexually active during their participation in the study).
- •i)Serum follicle-stimulating hormone (FSH) level for postmenopausal women consistent with postmenopausal status as per the central reference laboratory for
- •women with amenorrhea for at least 6 months and < 18 months before screening
- •(unless they are surgically sterile).
- •j)Body Mass Index of = 40 kg/m2 (Appendix J).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly
排除标准
- •a. Currently on or have been treated in the past year with insulin regimens that include bolus insulins (e.g. regular insulin, rapid acting analogs, or premixed insulin) or use of Continuous Subcutaneous Insulin Infusion (CSII) (Note: this would not include the need for insulins in the settings of acute illness or hospitalization).
- •b. Has a history of type 1 diabetes mellitus (T1DM), or diabetic ketoacidosis (DKA), or secondary forms of diabetes such as cystic fibrosis.
- •c. Known hypersensitivity or allergy to insulin-glargine or its excipients or any other
- •d. Two or more severe hypoglycemic viii episodes within the prior year. e. Hypoglycemia unawareness defined by history.
- •f.Patients who eat only 1 meal per day.
- •g. Has a history of proliferative diabetic retinopathy, as defined by the application of focal or panretinal photocoagulation or vitrectomy in the 6 months before screening or any other unstable (rapidly progressing) retinopathy that may
- •require surgical treatment (including laser photocoagulation) during the study.
- •h. Is currently unstable and/or has moderate-to-severe illness, in the Investigator’s judgment including (but not limited to):
- •1. Cardiovascular disease (including cardiac arrhythmias, myocardial infarction within last year, peripheral vascular disease); New York Heart Association (NYHA) Functional Class III or IV (Appendix K: NYHA Classification of Heart Failure);
- •2. Uncontrolled hypertension (either treated or untreated) defined as a systolic blood pressure = 160 mmHg or a diastolic blood pressure = 100 mmHg at screening.
- •3. Hematological disease, hematocrit outside the range of 20% to 60% at
- •screening, hemolytic anemia, thalassemia, sickle cell anemia, G6PD deficiency, or any known hemoglobinopathy or known abnormality that would affect measurement of hemoglobin A1C and including taking any medication known to affect red cell survival.
- •4. Respiratory disease.
- •5. Hepatic disease: including elevated alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels (greater than 2 fold above the upper limit of normal [ULN]) and bilirubin above the normal range at
- •screening unless in the opinion of the Investigator and agreed upon by the medical monitor that the findings are consistent with Gilbert's disease.
- •6. Renal disease: including, serum creatinine > 2.0 mg/dl (176.8 µmol/l) or if currently taking Metformin = 1.5 mg/dl (= 132.6 µmol/l) for men or
- •= 1.4 mg/dl (= 123.8 µmol/l) for women.
- •7. Gastrointestinal disease, including history of clinically significant gastroparesis.
- •8. Endocrine/metabolic disorders (Exception: T2DM, treated dyslipidemia,
- •treated hypothyroidism).
- •9. Thyroid stimulating hormone (TSH) > 10 µIU/ml at screening. (Note: patients on medication for hypothyroidism must be on fixed stable doses for at least 3 months prior to screening with no changes anticipated for the duration of the study).
- •10. Neurologic disease (including any history of seizures; stroke within the past year) or psychiatric disease, including schizophrenia, alcohol or substance abuse within the past 2 years; eating disorders. (Exception:
- •mood disorders or depression under control with or without stable antidepressant therapy).
- •11. Diagnosis and/or treatment of malignant neoplasms in the past 5 years. (Exception: adequately treated basal-cell or squamous-cell skin cancers).
- •12. History of recent major surgery within 6 months, or minor surgery within 3 months (such
研究者
相似试验
招募中
不适用
Glycaemic control in patients with type 2 diabetes and colorectal- or breast cancer treated with curative intentType 2 diabetes (T2DM)Breast cancer/borstkankerColorectal cancer/colorectale kankerHypertension/hypertensieDyslipidemia/dyslipidemieNL-OMON23282Diabetes Kenniscentrum Zwolle156
尚未招募
不适用
Glycemic control with Low Glycemic Index preparations of Kerala cuisine in subjects with Type 2 Diabetes.CTRI/2019/12/022425Amrita Institute of Medical Sciences and Research Centre
已完成
2 期
To Observe the Average Blood Glucose level in Diabetic PatientsCTRI/2018/06/014350ational Institute of Siddha100
尚未招募
3 期
Comparison of efficacy and safety of different doses of metformin in women with gestational diabetes mellitusCTRI/2023/11/059803All India Institute of Medical Sciences New Delhi
已完成
4 期
IRA-PRIME: A trial comparing the time period with blood sugar control using Victoza® (liraglutide) vs. oral antidiabetic treatment for up to 104 weeks of treatment in subjects with type 2 diabetes in a primary care settingCTRI/2016/09/007312ovo Nordisk India Private Ltd207